We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Review of LUMEVOQ® dossier to resume compassionate access program in France is ongoing; in parallel, work continues on the new RECOVER Phase III clinical trial and marketing application to the MHRA ...

Reducing the number of intravitreal injections to treat age-related macular degeneration (AMD) is a top priority in current ...

Retinal Biologics MarketThe Retinal Biologics Market generated USD 19.96 billion in revenue in 2021 and is projected to grow to USD 41.92 billion by 2028, expanding at a CAGR of 11.1% from 2022 to ...

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing ...

CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716, a novel therapeutic candidate ...

The Ocular Therapeutix logo and DEXTENZA ® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™ ...

This is a developing news story. Please check back soon for updates. The FDA approved expanded prescribing information for ...